In today’s episode, we welcome Dr. Antonio Matrone, an endocrinologist at the University of Pisa, to discuss the many factors involved in treatment decision-making and strategies for the management of patients with advanced thyroid cancer where an oncogenic driver has been identified.
References
- Matrone A et al. Differentiated thyroid cancer, from active surveillance to advanced therapy: Toward a personalized medicine. Front Endocrinol (Lausanne) 2019;10:884
- Sherman SI. Evolution of targeted therapies for thyroid carcinoma. Trans Am Clin Climatol Assoc 2019;130:255–265
- Filetti S et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol 2022;33(7):P674–P684
- Capdevila J et al. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era. Cancer Treat Rev 2022;106:102380
- Dabrafenib highlights of prescribing information. 2022
- Wirth LJ et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020;383:825–835
- Josfeld L et al. Cancer patient’s perspective on shared decision-making and decision aids in oncology. J Cancer Res Clin Oncol 2021;147:1725–1732
Target Audience:
Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.
Learning Objective:
- Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings
- Discuss “precision medicine” and new technologies, including “liquid biopsy”
- Review the organisation of care and strategies for more efficient care delivery
These learning objectives are for the podcast series. This episode focuses on the first and third objective.
Funding Information:
This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.
Staff Disclosure:
Dr. Matrone declares the following:
Consultant - Eli Lilly
